search

Active clinical trials for "Neoplasms"

Results 341-350 of 64586

Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell...

Oral Squamous Cell Carcinoma

TPF is still recommended as the preferred induction chemotherapy regimen for nonsurgical treatment of patients with LA HNSCC. Based on the KEYNOTE-048 study, all major guidelines recommend PD-1 monotherapy or PD-1 combined with chemotherapy as the new first-line standard treatment for patients with advanced HNSCC. The immunotherapy in operable LA HNSCC was also explored as neoadjuvant therapy due to the excellent data in advanced HNSCC. These explorations have also achieved good results. Therefore, this study aims to explore the pathological remission rate, the long-term benefit and safety of Tislelizumab combined with albumin paclitaxel, cisplatin and fluorouracil for locally advanced oral squamous cell carcinoma.

Recruiting23 enrollment criteria

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Advanced CancerMetastatic Cancer1 more

This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.

Recruiting10 enrollment criteria

A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

MelanomaUrothelial Carcinoma4 more

Safety study of RC198 in Subjects with Solid Tumors.

Recruiting69 enrollment criteria

Acceptance and Commitment Therapy in Tuberous Sclerosis Complex

Tuberous Sclerosis Complex

The study will assess the acceptability and feasibility of a randomised controlled trial of 6-12 sessions of remotely-delivered Acceptance and Commitment Therapy (ACT) versus waitlist control. Waitlist control will involve a delay in the offer of ACT sessions for 12 weeks. Participants may access all services as usual in this time. Follow-up assessments will be conducted at 12-, 24 and 48 weeks post-randomisation to measure effectiveness.

Recruiting12 enrollment criteria

PRE-I-SPY Phase I/Ib Oncology Platform Program

HER2-positive Breast CancerMetastatic Cancer17 more

I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.

Recruiting39 enrollment criteria

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Lung CancerSmall-cell Lung Cancer1 more

This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.

Recruiting28 enrollment criteria

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated...

LymphomaLarge B-Cell1 more

In the present trial the chemotherapy- light treatment concept R-Pola-Glo will be evaluated that combines the anti-CD20 antibody rituximab (R) with the ADC polatuzumab vedotin (Pola) and the (BiMabs) glofitamab (Glo) in elderly and/or medical unfit and previously untreated patients with aggressive B-cell lymphoma. The outcome and feasibility data obtained here will be used for further clinical development of this new chemolight triple combination.

Recruiting52 enrollment criteria

A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)

Non-small Cell Lung Cancer

This is a phase I, open-label, dose-escalation trial of TG6050 administered by single or repeated IV infusion(s).

Recruiting35 enrollment criteria

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple...

Multiple MyelomaRelapse Multiple Myeloma

Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy. Participation in this research will last about 6 -24 months, but it may be less or more depending on your response to treatment.

Recruiting52 enrollment criteria

HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC

Hepatocellular Carcinoma

Zoledronic acid was initially used for bone metastases in various malignancies. However, it is unknown whether hepatic arterial infusion chemotherapy combined with zoledronic acid can improve overall survival of unresectable hepatocellular carcinoma.

Recruiting25 enrollment criteria
1...343536...6459

Need Help? Contact our team!


We'll reach out to this number within 24 hrs